Title: Molecular mechanisms of acquired proteasome inhibitor resistance.
Journal: Journal of medicinal chemistry 20121213
Title: CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
Journal: Leukemia research 20121101
Title: Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE.
Journal: International immunopharmacology 20120101
Title: Analysing properties of proteasome inhibitors using kinetic and X-ray crystallographic studies.
Journal: Methods in molecular biology (Clifton, N.J.) 20120101
Title: Drugs: More shots on target.
Journal: Nature 20111214
Title: Novel proteasome inhibitors to overcome bortezomib resistance.
Journal: Journal of the National Cancer Institute 20110706
Title: Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study.
Journal: Journal of mass spectrometry : JMS 20101101
Title: Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Journal: Journal of medicinal chemistry 20101014
Title: The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan.
Journal: British journal of haematology 20100201
Title: CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Journal: Blood 20080301
Title: Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
Journal: Journal of medicinal chemistry 20080227
